leukemia

[PLOS One] Investigators combined FX-9 with the currently approved therapeutic agents doxorubicin, carboplatin, the demethylating substance azacitidine as well as further potentially antitumorigenic agents such as dichloroacetic acid in order to evaluate the respective synergistic potential.

[Cancer Gene Therapy] The expression of miR-548ac and TRIM28 and the targeting relationship were identified, and the results demonstrated that the expression of miR-548ac was upregulated in acute myeloid leukemia (AML) cell lines and AML cell-secreted extracellular vesicles compared with CD34+ HSCs.

[Scientific Reports] The authors explored expression patterns and prognostic value of secretory carrier-associated membrane proteins (SCAMPs) and network analysis of SCAMPs-related signaling pathways in acute myeloid leukemia using Oncomine, GEPIA, cBioPortal, LinkedOmics, DAVID and Metascape databases.

[Blood Advances] Patients with VEXAS syndrome had a propensity toward developing cytopenia, myelodysplastic syndrome, multiple myeloma, and venous thromboembolism. Bone marrow from patients with VEXAS showed characteristic vacuolization of myeloid and erythroid precursors.

[Stem Cell Research & Therapy] Scientists discuss and explain the most recent advances in chimeric antigen receptor (CAR) T cell-based therapies targeting acute myeloid leukemia (AML) antigens and review the results of preclinical and clinical trials.

[Bio-Path Holdings, Inc.] Bio-Path Holdings, Inc. announced that the US FDA has reviewed and cleared the Investigational New Drug application for BP1002, the company’s second drug candidate, for an initial Phase I/Ib clinical trial that will evaluate the ability of BP1002 to treat refractory/relapsed acute myeloid leukemia patients.